<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04593992</url>
  </required_header>
  <id_info>
    <org_study_id>HP study</org_study_id>
    <nct_id>NCT04593992</nct_id>
  </id_info>
  <brief_title>HTEMS Treatment of Diabetic Polyneuropathy</brief_title>
  <acronym>HTEMS-RCT</acronym>
  <official_title>High-tone External Muscle Stimulation for Treatment of Diabetic Polyneuropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>West German Center of Diabetes and Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>gbo Medizintechnik AG</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>West German Center of Diabetes and Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      So far, there are no sufficient pharmacologic therapies for the treatment of diabetic&#xD;
      neuropathy. Therefore, we evaluated application of high-tone external muscle stimulation&#xD;
      (HTEMS) compared to placebo treatment in patients with diabetic neuropathy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients (n=80) with symptomatic diabetic neuropathy will be included into this randomized&#xD;
      controlled trial. Each intervention will be administered for a period of at least 30 min on&#xD;
      at leat 5 days in a week. Health impairments will be assessed using the neuropathy symptom&#xD;
      score (NSS) before, during and after intervention.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 20, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Neuropathy symptom score</measure>
    <time_frame>12 weeks</time_frame>
    <description>Neuropathic symptoms measured by the neuropathic symptom score (NSS). Range 1-10 with higher scores indicationg a worse outcome.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Diabetic Polyneuropathy</condition>
  <arm_group>
    <arm_group_label>HTEMS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High-tone external muscle stimulation 5 times within a week for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo stimulation 5 times within a week for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>HTEMS</intervention_name>
    <description>high-tone external muscle stimulation</description>
    <arm_group_label>HTEMS</arm_group_label>
    <other_name>HITOP 191 (gbo Medizintechnik AG, Rimbach, Germany)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo stimulation</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo treatment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  symptomatic diabetic neuropathy&#xD;
&#xD;
          -  stable oral analgesic regimen&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  history of drug or alcohol abuse&#xD;
&#xD;
          -  cardiac pacemaker or defibrillator&#xD;
&#xD;
          -  pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Stephan Martin, MD</last_name>
    <phone>+49(0)211-5660360</phone>
    <phone_ext>70</phone_ext>
    <email>stephan.martin@uni-duesseldorf.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>West-German Centre of Diabetes and Health, Düsseldorf Catholic Hospital Group</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40591</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephan Martin, MD</last_name>
      <phone>+49-(0)211-5660360</phone>
      <phone_ext>70</phone_ext>
      <email>stephan.martin@uni-duesseldorf.de</email>
    </contact>
    <investigator>
      <last_name>Stephan Martin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>October 14, 2020</study_first_submitted>
  <study_first_submitted_qc>October 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 20, 2020</study_first_posted>
  <last_update_submitted>January 11, 2021</last_update_submitted>
  <last_update_submitted_qc>January 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>West German Center of Diabetes and Health</investigator_affiliation>
    <investigator_full_name>Stephan Martin</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>diabetes</keyword>
  <keyword>neuropathy</keyword>
  <keyword>pain</keyword>
  <keyword>HTEMS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polyneuropathies</mesh_term>
    <mesh_term>Diabetic Neuropathies</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

